SCHEMBL2904839

SCHEMBL2904839

Fc1ccc(-c2ccc(-n3cc(CN4CCNCC4)c(-c4ccco4)n3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 0.52
ALDH1A1 P00352 11/20 0.47
KDM4E B2RXH2 8/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 1/20 0.47
MAPK1 P28482 2/20 0.46
POLB P06746 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
LMNA P02545 3/20 0.44
GAA P10253 2/20 0.44
TDP1 Q9NUW8 1/20 0.43
SSTR5 P35346 1/20 0.42
USP7 Q93009 1/20 0.38
MEN1 O00255 1/20 0.38
ALOX12 P18054 1/20 0.38
KMT2A Q03164 1/20 0.38
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.38
HTT P42858 2/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903064 0.91 ALDH1A1 (0.52) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2903263 0.89 ALDH1A1 (0.48) NPSR1ALDH1A1KDM4EMAPTNPC1
Morpholine SCHEMBL2905728 0.87 ALDH1A1 (0.49) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2905922 0.87 ALDH1A1 (0.52) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2909630 0.87 ALDH1A1 (0.62) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2904795 0.85 ALDH1A1 (0.52) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2905976 0.84 ALDH1A1 (0.54) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2909330 0.84 ALDH1A1 (0.54) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2907733 0.82 ALDH1A1 (0.47) NPSR1ALDH1A1KDM4EMAPTNPC1
SCHEMBL2902611 0.81 ALDH1A1 (0.53) NPSR1ALDH1A1KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A NPSR1 23/4885ALDH1A1 1336/4885KDM4E 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.